Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
14388 | 772 | 43.7 | 88% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
518 | 3 | ANGIOGENESIS//RETINOPATHY OF PREMATURITY//ENDOSTATIN | 20826 |
361 | 2 | ANGIOGENESIS//ENDOSTATIN//VEGF | 17372 |
14388 | 1 | METRONOMIC CHEMOTHERAPY//CIRCULATING ENDOTHELIAL CELLS//METRONOMIC | 772 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | METRONOMIC CHEMOTHERAPY | authKW | 2901318 | 16% | 59% | 125 |
2 | CIRCULATING ENDOTHELIAL CELLS | authKW | 2056794 | 14% | 50% | 105 |
3 | METRONOMIC | authKW | 808130 | 5% | 55% | 37 |
4 | BIOL SCI PLATFORM | address | 146477 | 1% | 37% | 10 |
5 | CELL BIOL CANC SCI | address | 129438 | 1% | 55% | 6 |
6 | LOW DOSE METRONOMIC CHEMOTHERAPY | authKW | 123597 | 1% | 63% | 5 |
7 | METRONOMIC THERAPY | authKW | 123587 | 1% | 31% | 10 |
8 | GEN HOSP LIVORNO | address | 118657 | 0% | 100% | 3 |
9 | METRONOMIC VINORELBINE | authKW | 118657 | 0% | 100% | 3 |
10 | CIRCULATING ENDOTHELIAL PROGENITORS | authKW | 109863 | 1% | 56% | 5 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 10488 | 60% | 0% | 461 |
2 | Hematology | 493 | 8% | 0% | 65 |
3 | Peripheral Vascular Diseases | 211 | 6% | 0% | 43 |
4 | Medicine, Research & Experimental | 143 | 6% | 0% | 48 |
5 | Pharmacology & Pharmacy | 134 | 10% | 0% | 79 |
6 | Pathology | 29 | 2% | 0% | 19 |
7 | Pediatrics | 24 | 3% | 0% | 23 |
8 | Medical Laboratory Technology | 23 | 1% | 0% | 9 |
9 | Obstetrics & Gynecology | 13 | 2% | 0% | 16 |
10 | Urology & Nephrology | 12 | 2% | 0% | 15 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOL SCI PLATFORM | 146477 | 1% | 37% | 10 |
2 | CELL BIOL CANC SCI | 129438 | 1% | 55% | 6 |
3 | GEN HOSP LIVORNO | 118657 | 0% | 100% | 3 |
4 | WHO ABORATING REFERENCE VIRAL HEPATITIS | 79104 | 0% | 100% | 2 |
5 | GENET EXPT | 72798 | 1% | 20% | 9 |
6 | CHILDRENS CANC AUSTRALIA | 59307 | 2% | 13% | 12 |
7 | HAEMOSTASIS THROMBOSIS VASC BIOL UNIT | 55793 | 3% | 6% | 24 |
8 | HEMATOL IMMUNOLUFR PHARM | 52735 | 0% | 67% | 2 |
9 | IRCCS FDN SAN MATTEO | 52735 | 0% | 67% | 2 |
10 | ADV LIVER DIS STUDY GRPFITERMAN DIGEST DIS | 39552 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | NEOPLASIA | 6762 | 2% | 1% | 17 |
2 | ANGIOGENESIS | 3435 | 0% | 4% | 2 |
3 | NATURE REVIEWS CLINICAL ONCOLOGY | 3210 | 1% | 1% | 6 |
4 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 3072 | 3% | 0% | 24 |
5 | MOLECULAR CANCER THERAPEUTICS | 2785 | 2% | 0% | 17 |
6 | CLINICAL CANCER RESEARCH | 2204 | 4% | 0% | 29 |
7 | NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES A, LIFE SCIENCES | 1755 | 1% | 1% | 4 |
8 | PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS | 1745 | 1% | 1% | 4 |
9 | CANCER RESEARCH | 1491 | 5% | 0% | 39 |
10 | CYTOMETRY PART B-CLINICAL CYTOMETRY | 1413 | 1% | 1% | 5 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | CARRE, M , PASQUIER, E , ANDRE, N , (2014) METRONOMICS: TOWARDS PERSONALIZED CHEMOTHERAPY?.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 11. ISSUE 7. P. 413 -431 | 83 | 46% | 46 |
2 | PENEL, N , ADENIS, A , BOCCI, G , (2012) CYCLOPHOSPHAMIDE-BASED METRONOMIC CHEMOTHERAPY: AFTER 10 YEARS OF EXPERIENCE, WHERE DO WE STAND AND WHERE ARE WE GOING?.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 82. ISSUE 1. P. 40 -50 | 58 | 78% | 32 |
3 | BOCCI, G , KERBEL, RS , (2016) PHARMACOKINETICS OF METRONOMIC CHEMOTHERAPY: A NEGLECTED BUT CRUCIAL ASPECT.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 13. ISSUE 11. P. 659 -673 | 66 | 51% | 1 |
4 | ROMITI, A , COX, MC , SARCINA, I , DI ROCCO, R , D'ANTONIO, C , BARUCCA, V , MARCHETTI, P , (2013) METRONOMIC CHEMOTHERAPY FOR CANCER TREATMENT: A DECADE OF CLINICAL STUDIES.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 72. ISSUE 1. P. 13-33 | 74 | 44% | 25 |
5 | SAMUEL, DP , WEN, PY , KIERAN, MW , (2009) ANTIANGIOGENIC (METRONOMIC) CHEMOTHERAPY FOR BRAIN TUMORS: CURRENT AND FUTURE PERSPECTIVES.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 18. ISSUE 7. P. 973-983 | 66 | 62% | 7 |
6 | CAZZANIGA, ME , DEL CONTE, A , MENCOBONI, M , BOCCI, G , CAMERINI, A , ADDEO, R , NOLE, F , MUNZONE, E , COLLOVA, E , PAPALDO, P , ET AL (2016) METRONOMIC ORAL VINORELBINE IN ADVANCED BREAST CANCER AND NON-SMALL-CELL LUNG CANCER: CURRENT STATUSAND FUTURE DEVELOPMENT.FUTURE ONCOLOGY. VOL. 12. ISSUE 3. P. 373 -387 | 39 | 80% | 1 |
7 | CRAMAROSSA, G , LEE, EK , SIVANATHAN, L , GEORGSDOTTIR, S , LIEN, K , DELOS SANTOS, K , CHAN, K , EMMENEGGER, U , (2014) A SYSTEMATIC LITERATURE ANALYSIS OF CORRELATIVE STUDIES IN LOW-DOSE METRONOMIC CHEMOTHERAPY TRIALS.BIOMARKERS IN MEDICINE. VOL. 8. ISSUE 6. P. 893 -911 | 55 | 60% | 5 |
8 | MUNZONE, E , COLLEONI, M , (2015) CLINICAL OVERVIEW OF METRONOMIC CHEMOTHERAPY IN BREAST CANCER.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 12. ISSUE 11. P. 631 -644 | 55 | 46% | 11 |
9 | LOVEN, D , HASNIS, E , BERTOLINI, F , SHAKED, Y , (2013) LOW-DOSE METRONOMIC CHEMOTHERAPY: FROM PAST EXPERIENCE TO NEW PARADIGMS IN THE TREATMENT OF CANCER.DRUG DISCOVERY TODAY. VOL. 18. ISSUE 3-4. P. 193-201 | 43 | 62% | 23 |
10 | SCHAROVSKY, OG , MAINETTI, LE , ROZADOS, VR , (2009) METRONOMIC CHEMOTHERAPY: CHANGING THE PARADIGM THAT MORE IS BETTER.CURRENT ONCOLOGY. VOL. 16. ISSUE 2. P. 91-99 | 49 | 62% | 9 |
Classes with closest relation at Level 1 |